3/31
08:10 pm
bbio
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]
Low
Report
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]
3/30
03:30 pm
bbio
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
Low
Report
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
3/30
07:38 am
bbio
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 [Yahoo! Finance]
Low
Report
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 [Yahoo! Finance]
3/30
07:30 am
bbio
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Low
Report
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
3/28
10:28 pm
bbio
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? [Yahoo! Finance]
Low
Report
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? [Yahoo! Finance]
3/23
07:30 am
bbio
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Low
Report
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
3/20
04:45 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/20
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/18
02:22 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by Mizuho from $91.00 to $106.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by Mizuho from $91.00 to $106.00. They now have an "outperform" rating on the stock.
3/15
11:31 am
bbio
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]
Low
Report
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]
3/12
10:01 pm
bbio
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
Low
Report
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
3/12
11:07 am
bbio
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
3/11
02:25 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
3/11
02:00 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
3/10
10:01 pm
bbio
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
Medium
Report
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
3/10
05:04 pm
bbio
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
Medium
Report
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
3/10
03:37 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
3/10
09:00 am
bbio
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
High
Report
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
3/7
04:39 pm
bbio
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
Low
Report
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
3/7
02:33 am
bbio
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline [Yahoo! Finance]
Low
Report
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline [Yahoo! Finance]
3/6
10:36 am
bbio
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating [Yahoo! Finance]
Low
Report
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating [Yahoo! Finance]
3/4
07:30 am
bbio
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
Medium
Report
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
3/3
02:33 am
bbio
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]
Low
Report
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]
2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.